8-K: Myomo CEO, CFO Opt for RSUs Over Salary

Myomo's CEO and CFO voluntarily reduced their 2026 base salaries by 10% in exchange for restricted stock units valued at 115% of the foregone amount.

Summary

• Myomo, Inc. approved a salary-for-restricted stock units (RSUs) program for all salaried employees.
• CEO Paul Gudonis voluntarily elected to reduce his 2026 base salary by 10%, equivalent to $40,000, in exchange for RSUs with an aggregate grant date fair value equal to 115% of the foregone salary.
• CFO David Henry voluntarily elected to reduce his 2026 base salary by 10%, equivalent to $30,000, in exchange for RSUs with an aggregate grant date fair value equal to 115% of the foregone salary.
• The company retains the right, in its sole discretion, to terminate or modify the program at any time prior to January 12, 2026.
• If the program is terminated, no RSU grants will be made, and the officers' base salaries will remain unchanged.
• Subject to the company's right to terminate or modify, all such RSUs will be granted in equal quarterly installments, beginning on January 12, 2026.
• Each quarterly RSU grant will vest in full on the three-month anniversary of the grant date, subject to continuous service.

Sentiment

Score: 7

Explanation: The voluntary salary reduction for RSUs by top executives is generally a positive signal, indicating confidence in the company's future and a desire to align with shareholder interests. It also helps conserve cash. The potential for program termination before the grant date introduces a minor element of uncertainty.

Positives

• Reduces immediate cash outflow for executive compensation, potentially improving the company's cash flow.
• Aligns executive incentives with long-term shareholder value through increased equity ownership.
• Demonstrates management's confidence in the company's future stock performance.
• The 15% premium (115% RSU value for 100% foregone salary) provides an incentive for executives to participate in the program.

Negatives

• Potential for dilution for existing shareholders if a significant number of RSUs are issued across all salaried employees, although the filing specifically details only the CEO and CFO.
• Executives' compensation becomes more volatile, directly tied to the company's stock performance.

Risks

• The Company retains the right, in its sole discretion, to terminate or modify the salary-for-RSU program at any time prior to January 12, 2026.
• If the Company exercises its termination right, no RSU grants will be made, and the officers' base salaries will remain unchanged.
• The actual value realized by executives from the RSUs is subject to market fluctuations of the company's stock price.

Future Outlook

The program is set to begin RSU grants in equal quarterly installments starting January 12, 2026, with each grant vesting fully on its three-month anniversary, contingent on continuous service. The company retains the option to terminate or modify the program before the initial grant date.

Management Comments

• Paul Gudonis, the Company's Chief Executive Officer, voluntarily elected to reduce his base salary for 2026 by 10%.
• David Henry, the Chief Financial Officer of the Company, voluntarily elected to reduce his base salary for 2026 by 10%.

Industry Context

This type of executive compensation strategy, where cash salary is exchanged for equity, is a common practice, particularly for growth-oriented companies or those aiming to conserve cash. It aligns management's interests with shareholders by making their compensation directly tied to the company's stock performance, often seen during periods of strategic investment or when a company seeks to optimize its balance sheet.

Comparison to Industry Standards

• Many technology and biotech companies, especially those in growth phases or with fluctuating cash flows, utilize RSU programs to attract and retain talent while managing cash burn.
• The 115% RSU value for a 100% salary reduction is a common incentive structure, offering a premium for executives taking on equity risk, similar to programs observed at companies prioritizing cash conservation and long-term alignment.
• The quarterly vesting schedule over a short period (three months per grant) is relatively aggressive, aiming to provide more immediate equity exposure and retention incentive compared to longer annual vesting schedules often seen in more mature companies.

Corporate Governance

Related Party Transactions

• The program involves voluntary salary reductions by the CEO, Paul Gudonis, and the CFO, David Henry, in exchange for RSUs. These are transactions with key management personnel.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with long-term shareholder value; potential for minor dilution from RSU issuance.
• Employees: The program is open to all salaried employees, potentially offering a new compensation option and fostering a sense of shared ownership.
• Creditors: Improved cash flow management due to reduced cash compensation could be viewed positively.

Next Steps

• The Company will decide whether to terminate or modify the salary-for-RSU program prior to January 12, 2026.
• If the program proceeds, RSU grants will commence in equal quarterly installments starting January 12, 2026.
• Each quarterly RSU grant will vest in full on the three-month anniversary of the grant date, subject to the officers' continuous service.

Key Dates

Recommendation

The decision by Myomo's CEO and CFO to exchange a portion of their cash salary for restricted stock units is a positive signal, demonstrating management's confidence in the company's future and a commitment to aligning with shareholder interests. This move also helps conserve cash, which is beneficial for a growth-oriented company. However, without broader financial performance data or strategic updates, this compensation change alone is not a strong enough catalyst for a 'buy' recommendation. It's a prudent internal financial and governance move, suggesting a 'hold' while awaiting further operational and financial results.

Keywords

Myomo, MYO, SEC filing, 8-K, executive compensation, restricted stock units, RSUs, salary reduction, corporate governance, cash flow, incentive plan